Evaluation of Efficacy of QR 678 and QR678 Neo Hair Growth Factor Formulation for the Treatment of Female Pattern Alopecia in Patients with PCOS A Prospective Study

Abstract

Background: Hair is an essential identity of women. Femininity, sexuality, attractive-
ness, and personality are symbolically linked to a woman’s hair. Female pattern hair
loss is found in 20%-30% of patients with polycystic ovary syndrome (PCOS).

Aim: The aim of the present study was to evaluate the efficacy of QR678® and QR678
Neo® therapy in the treatment of female alopecia with PCOS.

Method: A total of 20 females diagnosed with PCOS in the age 25-50 years, with
complaints of female pattern alopecia with Ludwig, grades I, and II were selected for
the study. At each visit, 1.5 ml solution of QR678® was injected in the scalp skin of
patients. A total of eight sessions were performed at an interval of 3 week each. All
the patients were evaluated with standard global photography at baseline, 4th and
8th session, and 2 months after 8th session.

Result: Marked improvement was seen in the global photographic assessment score
(mean = 8) which was maintained for over 1 year. In videomicroscopic assessment,
after four sessions the patients had 8.07 fewer vellus hair, 6.07 more terminal hair,
and average hair shaft diameter was 0.82 μm wider. After eight sessions, they had
11.66 fewer vellus hair, 13.77 more terminal hair, and hair shaft diameter was 2.86 μm
wider than at baseline.

Conclusion: Intra-dermal injections of QR 678® hair growth factor formulation is an
effective option for female pattern alopecia with PCOS. This is the first of its kind
study using QR678® and QR678 Neo® in PCOS patients.

For full article open PDF